GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albany Molecular Research Inc (NAS:AMRI) » Definitions » Piotroski F-Score

Albany Molecular Research (Albany Molecular Research) Piotroski F-Score : 0 (As of Apr. 25, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Albany Molecular Research Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Albany Molecular Research has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Albany Molecular Research's Piotroski F-Score or its related term are showing as below:


Albany Molecular Research Piotroski F-Score Historical Data

The historical data trend for Albany Molecular Research's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albany Molecular Research Piotroski F-Score Chart

Albany Molecular Research Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 7.00 4.00 5.00 2.00

Albany Molecular Research Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 2.00 2.00 3.00 4.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun17) TTM:Last Year (Jun16) TTM:
Net Income was -23.425 + -15.411 + -10.692 + -10.247 = $-59.8 Mil.
Cash Flow from Operations was -10.013 + 21.407 + -6.41 + 14.93 = $19.9 Mil.
Revenue was 152.738 + 191.322 + 163.822 + 172.932 = $680.8 Mil.
Gross Profit was 29.252 + 38.736 + 41.044 + 41.217 = $150.2 Mil.
Average Total Assets from the begining of this year (Jun16)
to the end of this year (Jun17) was
(806.506 + 1258.083 + 1209.648 + 1163.529 + 1242.374) / 5 = $1136.028 Mil.
Total Assets at the begining of this year (Jun16) was $806.5 Mil.
Long-Term Debt & Capital Lease Obligation was $195.6 Mil.
Total Current Assets was $403.9 Mil.
Total Current Liabilities was $592.7 Mil.
Net Income was -4.17 + 1.785 + -10.067 + -21.267 = $-33.7 Mil.

Revenue was 104.579 + 126.412 + 105.579 + 120.81 = $457.4 Mil.
Gross Profit was 24.375 + 33.896 + 26.216 + 38.596 = $123.1 Mil.
Average Total Assets from the begining of last year (Jun15)
to the end of last year (Jun16) was
(602.584 + 819.868 + 865.567 + 834.213 + 806.506) / 5 = $785.7476 Mil.
Total Assets at the begining of last year (Jun15) was $602.6 Mil.
Long-Term Debt & Capital Lease Obligation was $370.8 Mil.
Total Current Assets was $256.7 Mil.
Total Current Liabilities was $102.7 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Albany Molecular Research's current Net Income (TTM) was -59.8. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Albany Molecular Research's current Cash Flow from Operations (TTM) was 19.9. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun16)
=-59.775/806.506
=-0.074116

ROA (Last Year)=Net Income/Total Assets (Jun15)
=-33.719/602.584
=-0.05595734

Albany Molecular Research's return on assets of this year was -0.074116. Albany Molecular Research's return on assets of last year was -0.05595734. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Albany Molecular Research's current Net Income (TTM) was -59.8. Albany Molecular Research's current Cash Flow from Operations (TTM) was 19.9. ==> 19.9 > -59.8 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun17)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun16 to Jun17
=195.591/1136.028
=0.17217093

Gearing (Last Year: Jun16)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun15 to Jun16
=370.798/785.7476
=0.47190472

Albany Molecular Research's gearing of this year was 0.17217093. Albany Molecular Research's gearing of last year was 0.47190472. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun17)=Total Current Assets/Total Current Liabilities
=403.912/592.659
=0.68152513

Current Ratio (Last Year: Jun16)=Total Current Assets/Total Current Liabilities
=256.653/102.715
=2.49869055

Albany Molecular Research's current ratio of this year was 0.68152513. Albany Molecular Research's current ratio of last year was 2.49869055. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Albany Molecular Research's number of shares in issue this year was 42.52. Albany Molecular Research's number of shares in issue last year was 34.935. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=150.249/680.814
=0.22069023

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=123.083/457.38
=0.26910446

Albany Molecular Research's gross margin of this year was 0.22069023. Albany Molecular Research's gross margin of last year was 0.26910446. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun16)
=680.814/806.506
=0.84415243

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun15)
=457.38/602.584
=0.75903111

Albany Molecular Research's asset turnover of this year was 0.84415243. Albany Molecular Research's asset turnover of last year was 0.75903111. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+1+0+0+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Albany Molecular Research has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Albany Molecular Research  (NAS:AMRI) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Albany Molecular Research Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Albany Molecular Research's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Albany Molecular Research (Albany Molecular Research) Business Description

Traded in Other Exchanges
N/A
Address
Albany Molecular Research provides research services to pharmaceutical, biotechnology, and chemical companies. The company offers services like design and modification of potential lead compounds, purification technique development, quality control, bulk ingredient stability studies, and regulatory documentation preparation. The company has entered into collaborative agreements with companies like Eli Lilly and Cambrex. Albany's acquisition of Organichem provided the company with commercial manufacturing capabilities.
Executives
Anthony J Maddaluna director PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
Felicia I Ladin officer: SVP, Treasurer & CFO 26 CORPORATE CIRCLE, ALBANY NY 12203
David H Deming director C/O BETTER FOR YOU WELLNESS, INC., 1349 EAST BROAD ST, COLUMBUS OH 43205
William S Marth director, officer: President and CEO 236 GROVE STREET, WELLESLEY MA 02482
Lori M. Henderson officer: SVP, Secretary & Gen Counsel MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Una S Ryan director 329 HAMMOND STREET, CHESTNUT HILL MA 02467
Veronica Gh Jordan director C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Gabriel Leung director C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Michael A Luther officer: Senior VP, Discovery Services 21 CORPORATE CIRCLE, ALBANY NY 12203
Mark T Frost officer: Chief Financial Officer 21 CORPORATE CIRCLE, PO BOX 15098, ALBANY NY 12033-5098
David P Waldek officer: Chief Financial Officer ALBANY MOLECULAR RESEARCH INC, 21 CORPORATE CIRCLE PO BOX 15098, ALBANY NY 12212-5098

Albany Molecular Research (Albany Molecular Research) Headlines

No Headlines